CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
NCT04406610 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL
Last updated 2020-07-16
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Conditions
- Glioma of Brain
- CAR-T Cell Immunotherapy
Interventions
- BIOLOGICAL
-
GD2 CAR-T immunotherapy
Antigen-specific T cell therapy
Sponsors & Collaborators
-
Fuda Cancer Hospital, Guangzhou
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 30 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-09-01
- Primary Completion
- 2016-08-15
- Completion
- 2016-10-15
More Related Trials
-
Clinical Study of Carbon Ion Radiotherapy for High-grade Glioma
NCT06831773 ·Status: RECRUITING ·Phase: NA
-
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
NCT06815029 ·Status: RECRUITING ·Phase: PHASE1
-
CD147-CART Cells in Patients With Recurrent Malignant Glioma.
NCT04045847 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
WL276 CAR-T Cell Therapy for CD276 Positive Recurrent or Progressive Glioblastoma Patients
NCT06691308 ·Status: NOT_YET_RECRUITING ·Phase: EARLY_PHASE1
-
Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme
NCT02937844 ·Status: UNKNOWN ·Phase: PHASE1
-
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
NCT00980343 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of in Vitro Antitumor Activity of GD2 CAR-T Cells in Glioblastoma
NCT06764537 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Single-arm, Open, Exploratory Clinical Study of Allogeneic CAR-T Cells in the Treatment of Relapsed/Refractory Brain Gliomas With Positive CD70 Expression
NCT06828341 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
NCT00730613 ·Status: COMPLETED ·Phase: PHASE1
-
Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme
NCT03170141 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG)
NCT04196413 ·Status: RECRUITING ·Phase: PHASE1
-
Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
NCT02709226 ·Status: COMPLETED ·Phase: PHASE1
-
Pilot Study of NKG2D CAR-T in Treating Patients With Recurrent Glioblastoma
NCT04717999 ·Status: UNKNOWN ·Phase: NA
-
IL13Rα2 CAR-T for Patients With r/r Glioma
NCT06355908 ·Status: SUSPENDED ·Phase: PHASE1
-
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma
NCT05868083 ·Status: UNKNOWN ·Phase: PHASE1
-
Assessment of Novel Metabolic Imaging Modalities as A Predictor Of Therapeutic EfficacyiIn Glioblastoma (GBM)
NCT06855628 ·Status: SUSPENDED ·Phase: PHASE2
-
A Phase I Clinical Trial of a mRNA Vaccine for Recurrent or Progressive High-grade Glioma
NCT07306299 ·Status: RECRUITING ·Phase: PHASE1
-
Low Dose Radiation Therapy for Glioblastoma Multiforme
NCT01466686 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
NCT01082926 ·Status: COMPLETED ·Phase: PHASE1
-
The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the rGBM
NCT06616727 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM
NCT03283631 ·Status: TERMINATED ·Phase: PHASE1
-
Study of DC Vaccination Against Glioblastoma
NCT01567202 ·Status: UNKNOWN ·Phase: PHASE2
-
EGFRBi-Armed Autologous T Cells in Treating Patients With Recurrent or Refractory Glioblastoma
NCT02521090 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
NCT02209376 ·Status: TERMINATED ·Phase: PHASE1
-
The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients
NCT05063682 ·Status: UNKNOWN ·Phase: PHASE1